Iterum Therapeutics
About Iterum Therapeutics
Iterum Therapeutics Limited: Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world.We are pursuing a balanced development strategy with multiple opportunities intended to treat the organisms responsible for many serious infections, which the Centers for Disease Control (CDC) has determined to be inadequately addressed by current therapies1.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Corey N. Fishman
CSO: Michael Dunne, MD
CFO: Judith M. Matthews
VP, Operations: Benjamin M. PE
VP, Development: Sailaja Puttagunta, MD
VP, Business Development & Supply Chain: John J. White
CAREER:
Please click here for Iterum Therapeutics' job opportunities.
102 articles about Iterum Therapeutics
-
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionTopline results expected in Q1 2020
12/26/2019
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 1 clinical trial in uncomplicated urinary tract infections (uUTI).
-
Clinical Catch-Up: December 9-13
12/16/2019
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look. -
Iterum Still Hopeful for its New Sulopenem Antibiotic Despite Narrowly Missing Mark in Late-Stage...
12/11/2019
It missed the primary endpoint by a narrow margin—so narrow, in fact, it comes to about a single patient. -
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
12/10/2019
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI).
-
Clinical Catch-Up: November 18-22
11/25/2019
As usual, it was a busy week for clinical trial updates. Here’s a look. -
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract InfectionTopline results expected in Q1 2020
11/18/2019
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the completion of patient enrollment in its Sulopenem for Resistant Enterobacteriaceae (SURE) 2 clinical trial in complicated urinary tract infections (cUTI).
-
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
11/12/2019
Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2019 and provided an update on its clinical programs.
-
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
10/5/2018
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, will present data on sulopenem, its novel oral and IV penem antibiotic, in three poster presentations today at IDWeek 2018 in San Francisco.
-
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
9/18/2018
Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, today announced its initiation of the second and third of three planned Phase 3 clinical trials for sulopenem, Iterum’s lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections.
-
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
8/14/2018
As of June 30, 2018, Iterum had cash, cash equivalents and short-term investments of $135.3 million and approximately 14.2 million shares outstanding
-
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
-
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area. -
Iterum Therapeutics to Present Data on Prevalence of Resistant Infections and In Vitro Activity of its Novel Antibiotic Sulopenem
6/6/2018
Iterum Therapeutics plc will present four posters at the American Society of Microbiology MICROBE meeting
-
Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals
5/29/2018
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs. -
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
-
Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.
-
Iterum Therapeutics Presents Data on Prevalence of Resistant Infections and Activity of its Novel Antibiotic Sulopenem
4/20/2018
More than 20 per cent of patients with outpatient urinary tract infections (UTIs) receive an antibiotic to which the responsible pathogen is not susceptible
-
Iterum Reveals New U.S. Maps Highlighting Antibiotic Resistance 'Hotspots'
10/4/2017
-
Iterum Gains Important Support For Development Of Novel Oral Antibiotic, Sulopenem
7/25/2017
-
Star R&D Duo Nabs $65 Million for Iterum to Develop Shelved Pfizer Antibiotic
5/19/2017